(Q37736742)

22 August 2017

1 reference

title

New drugs in migraine treatment and prophylaxis: telcagepant and topiramate (English)

1 reference

22 August 2017

1 reference

0 references

Lars Edvinsson

1

1 reference

22 August 2017

Mattias Linde

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

21 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

376

1 reference

22 August 2017

issue

9741

1 reference

22 August 2017

page(s)

645-655

1 reference

Cost of disorders of the brain in Europe

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Neurophysiological features of the migrainous brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Origin of pain in migraine: evidence for peripheral sensitisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

CGRP-receptor antagonism in migraine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Neurobiology in primary headaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Central nervous system binding sites for calcitonin and calcitonin gene-related peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distrib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-relate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Rizatriptan has central antinociceptive effects against durally evoked responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Randomized, controlled trial of telcagepant for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

CGRP antagonists: unravelling the role of CGRP in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Pathophysiological basis of migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate in migraine prevention: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate: a new antiepileptic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Pharmacokinetic interactions of topiramate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na+ ion channel blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate modulates excitability of the occipital cortex when measured by transcranial magnetic stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate inhibits trigeminovascular activation: an intravital microscopy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: therapeutic implications for migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Suppression of cortical spreading depression in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate in migraine prevention: results of a large controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Anticonvulsants in migraine prophylaxis: a Cochrane review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Migraines with and without aura and their response to preventive therapy with topiramate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Weight change associated with the use of migraine-preventive medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Efficacy of topiramate and valproate in chronic migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Efficacy and tolerability of topiramate in pediatric migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

The effect of migraine prophylaxis on migraine-related resource use and productivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Resource utilization impact of topiramate for migraine prevention in the managed-care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Cost-minimization analysis comparing topiramate with standard treatments in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Expert opinion: adherence to prophylactic migraine medication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960323-6

7 January 2021

10.1016/S0140-6736(10)60323-6

Identifiers

DOI

1 reference

22 August 2017

1 reference